Buscar
ANI Pharmaceuticals Inc
ANIPAñadir a la lista de seguimiento
83.050USD
+0.270+0.33%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
1.89BCap. mercado
20.19P/E TTM
Más Datos de ANI Pharmaceuticals Inc Compañía
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Información de ANI Pharmaceuticals Inc
Símbolo de cotizaciónANIP
Nombre de la empresaANI Pharmaceuticals Inc
Fecha de salida a bolsaMay 04, 2000
Director ejecutivoLalwani (Nikhil Suresh)
Número de empleados897
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
Dirección210 Main Street West
CiudadBAUDETTE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal56623
Teléfono12186343500
Sitio Webhttps://www.anipharmaceuticals.com/
Símbolo de cotizaciónANIP
Fecha de salida a bolsaMay 04, 2000
Director ejecutivoLalwani (Nikhil Suresh)
Ejecutivos de ANI Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
38.43K
-36.36%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.39K
-1.23%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
29.51K
+14.76%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
11.22K
+38.83%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de ANI Pharmaceuticals Inc?
Los cinco principales accionistas de ANI Pharmaceuticals Inc son: Mr. Chad Gassert
¿Cuántas instituciones poseen acciones de ANI Pharmaceuticals Inc (ANIP)?
A fecha de 2026Q1, 555 instituciones poseen acciones de ANI Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 23.15M, lo que representa el 101.74% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 57726.00.
¿Cuál es la mayor fuente de ganancias de ANI Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial Sales of generic pharmaceutical products generó la ganancia más alta para ANI Pharmaceuticals Inc, ascendiendo a 384.11M y representando el 43.48% de la ganancia total.